AAMS Psychiatry & Behavioral Health
ISSN: 2834-7210 (Print) | eISSN: 2834-7211 (Online)
Volume 02, Issue 11, Pages 16-30
DOI: 10.4103/aams.0498806
ORIGINAL ARTICLE

In our country, companies that carry out export and import operations must follow a specific procedure for conducting transactions involving foreign currency.

Shamsiyeva Sumbula[1] Musurmonova E'zoza[2]

Samarkand Institute of Economics and Service. Faculty of Accounting and Auditing[1,2].

Received: 2026-10-26 · Accepted: 2026-11-09

Abstract

Background: Companies conducting international trade must coordinate foreign-currency payments with banking documentation, contractual obligations, and applicable exchange regulations. For medical importers, administrative delays may threaten supply continuity. Uzbekistan was selected as the contextual setting because of the authors' institutional affiliation; the study does not provide a verified statement of current national law.
Objective: To demonstrate how documentary readiness could influence transaction processing and medical procurement using an explicitly synthetic dataset.
Methods: A descriptive workflow simulation comprised 120 invented transactions, including 80 medical imports and 40 export receipts. Transactions were assigned to complete-documentation or clarification-required pathways. Prespecified processing intervals and procurement buffers generated administrative delay and modeled buffer-exceedance outcomes. No company records, patients, or actual banking transactions were examined.
Results: Seventy-eight transactions followed the complete-documentation pathway and 42 required clarification. Assigned mean processing times were 3.0 and 8.0 working days, respectively, producing a weighted overall mean of 4.75 days. Among medical imports, modeled buffer exceedance occurred in 4 of 52 complete files and 10 of 28 clarification-required files. The resulting proportions were 7.7% and 35.7%.
Conclusions: This constructed example illustrates a plausible connection between transaction preparation and medical procurement vulnerability. It does not establish actual processing times, regulatory requirements, or causal effects. Empirical validation requires current legal review, bank-level timestamps, and independently measured inventory outcomes.

Keywords: foreign exchange, trade finance, medical imports, documentary compliance, procurement, Uzbekistan, simulation

1. Introduction

Reliable access to medicines, diagnostic reagents, and medical devices depends partly on the administrative and financial processes that support international trade. In our country, companies undertaking export and import operations must follow a prescribed procedure for transactions involving foreign currency. Although these requirements primarily serve financial oversight and regulatory compliance, their implementation may also have implications for health systems that

© 2026 AAMS Psychiatry & Behavioral Health. All rights reserved.

depend on imported medical products. Understanding these implications is relevant to continuity of care, particularly when clinically important supplies have limited substitutes or require timely replenishment.

Foreign currency transaction procedures may involve documentation, verification, authorization, and settlement steps, depending on the applicable regulatory framework. For companies supplying healthcare institutions, the time and resources required to complete these steps could influence procurement schedules and payment predictability. Delays or uncertainty may contribute to postponed shipments, reduced inventory buffers, or higher purchasing costs. However, such outcomes cannot be attributed to currency procedures alone. Exchange rate volatility, supplier capacity, transport disruptions, procurement practices, and domestic distribution constraints may produce similar effects and therefore require consideration.

The potential clinical relevance of these processes lies in their relationship with product availability rather than in financial compliance itself. Interruptions in access to essential medicines or diagnostic materials may necessitate therapeutic substitution, defer testing, or complicate scheduled treatment. Conversely, clear and consistently implemented transaction procedures may improve planning and accountability without materially disrupting supply. The direction and magnitude of these relationships are likely to vary across products, firms, and healthcare settings. Empirical assessment is therefore preferable to assuming that regulatory requirements are either uniformly burdensome or inherently protective.

This study examines the association between compliance with prescribed foreign currency transaction procedures and the continuity of imported medical product supply. It focuses on transaction processing times, procurement delays, and reported stock interruptions among companies supplying healthcare facilities, while considering relevant commercial and logistical factors. Where feasible, company records are assessed alongside facility inventory information to strengthen measurement and reduce reliance on retrospective perceptions. By distinguishing administrative processing from other sources of supply disruption, the study aims to generate evidence that can inform coordination between financial authorities, trading companies, and healthcare providers. Its purpose is to identify potentially modifiable operational barriers while recognizing the legitimate objectives of financial regulation.

The American Archives
OF MEDICAL SCIENCES
EDITOR-IN-CHIEF

2. Materials and Methods

A retrospective multicenter observational study was designed to examine whether the time required to complete mandatory foreign currency transaction procedures was associated with interruptions in imported medical supplies and related delays in patient care. The study would include public and private hospitals within one national jurisdiction, where companies conducting export and import operations must follow prescribed procedures for transactions involving foreign currency. The protocol specified a 24-month observation period and linked procurement records with routinely collected hospital service data.

Hospitals would be eligible if they maintained electronic procurement records, dated foreign currency processing documentation, inventory histories, and service cancellation logs. Eligible procurement episodes would involve imported medicines, diagnostic reagents, or medical devices intended for direct clinical use. Domestically purchased products without identifiable import documentation, donated supplies, and records lacking essential transaction dates would be excluded. All eligible episodes at participating hospitals would be assessed to reduce selection based on product availability or clinical outcomes.

The principal exposure would be foreign currency processing time, defined as calendar days between submission of a complete transaction application and documented authorization or settlement permitting payment to the overseas supplier. These milestones would be recorded separately when both were available. Trained reviewers would map the applicable procedural requirements using contemporaneous regulatory documents and institutional operating instructions, without assuming that every transaction followed an identical pathway. Additional variables would include application amendments, requests for supporting documents, payment method, transaction value, supplier location, product category, and procurement urgency.

© 2026 AAMS Psychiatry & Behavioral Health. All rights reserved.

The primary outcome would be a stockout lasting at least one complete day during the 90 days following application submission. A stockout would require inventory documentation showing no usable units of the requested product. Secondary outcomes would include stockout duration, emergency substitution, expedited purchasing, and scheduled clinical services postponed because the relevant product was unavailable. Clinical postponements would be attributed to supply interruption only when the documented reason explicitly identified product unavailability. Patient identifiers would not be extracted.

Potential confounders would include baseline stock coverage, historical product consumption, ordering frequency, supplier lead time, shipping disruptions, seasonal demand, hospital size, and procurement urgency. Duplicate transactions would be reconciled using purchase order identifiers. Two reviewers would independently assess a random 10% sample of records, resolving discrepancies by consensus. Missingness would be summarized by variable and hospital.

Associations would be estimated using mixed-effects regression, with hospital-level random intercepts and adjustment for prespecified confounders. Processing time would initially be modeled continuously, with nonlinear relationships evaluated using restricted cubic splines. Sensitivity analyses would exclude emergency orders, distinguish authorization from settlement delays, and restrict analyses to products with adequate baseline inventory. Multiple imputation would be considered for incomplete covariates when its assumptions were supportable; outcomes and essential exposure dates would not be imputed. Estimates would be reported with 95% confidence intervals and interpreted as associations rather than causal effects. Institutional ethics review and data-use authorization would be obtained before extraction, with encrypted storage, restricted access, and reporting limited to aggregated findings.

3. Results

The following results describe a simulated dataset constructed to illustrate a health-sector study of foreign-currency transaction procedures; they do not represent observed findings from an identified country. The dataset included 120 companies involved in importing or exporting medicines, medical devices, or diagnostic supplies. Across a 12-month observation period, these companies submitted 960 foreign-currency transactions, comprising 720 import payments and 240 export settlements. Ninety companies conducted imports only, 10 conducted exports only, and 20 conducted both activities. The median number of transactions per company was 7, with an interquartile range of 4–11.

Complete documentation at first submission was recorded for 648 transactions (67.5%), while 312 (32.5%) required correction or supplementary information. Completeness was assessed against the study's operational checklist of commercial documentation, transaction purpose, counterparty identification, and applicable bank declarations, rather than a verified national legal standard. Among incomplete submissions, the principal recorded deficiency was inconsistent invoice information in 116 cases (37.2%), missing supporting documents in 98 (31.4%), incomplete payment-purpose declarations in 62 (19.9%), and unresolved counterparty details in 36 (11.5%). Each transaction was assigned one principal deficiency for this descriptive classification.

Processing time was measured from initial submission to bank clearance. Transactions with complete initial documentation had a median processing time of 3 business days, compared with 8 business days for those requiring supplementation. Overall, 264 transactions (27.5%) exceeded the predefined threshold of five business days. This threshold was an analytical definition and was not interpreted as a statutory deadline. Processing outcomes by initial documentation status are summarized in Table 1.

Table 1. Simulated transaction outcomes by documentation completeness at initial submission

Outcome	Complete documentation (n = 648)	Supplementation required (n = 312)
Import payments, n	486	234
Export settlements, n	162	78
Processing time, median (interquartile range), business days	3 (2–5)	8 (5–12)

© 2026 AAMS Psychiatry & Behavioral Health. All rights reserved.

Processing exceeding five business days, n (%)	104 (16.0)	160 (51.3)
Additional bank queries, n (%)	72 (11.1)	246 (78.8)
Cleared within the observation window, n (%)	640 (98.8)	292 (93.6)

The unadjusted difference in delayed-processing proportions was 35.2 percentage points, calculated from the underlying counts. Transactions requiring supplementation were approximately 3.2 times as likely to exceed five business days as complete submissions. Additional bank queries were recorded in both groups, indicating that initial completeness did not eliminate subsequent clarification. Of all submissions, 932 (97.1%) were cleared within the observation window. The remaining 28 were still pending or had been withdrawn; these outcomes were not classified as regulatory violations.

A prespecified health-supply subset comprised 360 import payments linked to essential medicines, diagnostic reagents, or single-use clinical consumables. Of these, 270 had complete documentation and 90 required supplementation. Delivery after the originally scheduled date occurred in 45 complete submissions (16.7%) and 36 supplemented submissions (40.0%). A temporary inventory interruption at a receiving facility was recorded for 27 shipments in each group, corresponding to 10.0% and 30.0%, respectively. These shipment-level observations did not establish that foreign-currency processing was the sole cause of interruption, because transport and supplier delays could also contribute.

Among the 54 shipments associated with inventory interruptions, the median interruption duration was 4 calendar days, with an interquartile range of 2–7 days. Inventory interruptions were supply-chain outcomes rather than direct measures of patient harm. The dataset did not contain patient identifiers, treatment-level exposure information, or clinical outcomes, preventing assessment of missed doses, postponed procedures, or morbidity. Overall, documentation completeness was descriptively associated with faster transaction clearance and fewer supply disruptions, but the simulated, unadjusted comparisons did not establish causality or demonstrate compliance with any specific national foreign-currency regulation.

4. Discussion

This study examines the potential health-system implications of the procedures that companies must follow when conducting foreign-currency transactions for export and import operations. For medical products, these procedures are relevant because procurement may depend on overseas manufacturers, internationally priced contracts, and payment arrangements involving several financial intermediaries. The principal interpretive issue is therefore not whether foreign-exchange oversight is justified, but whether its implementation is compatible with predictable access to essential medicines, diagnostic materials, and medical equipment. Regulatory compliance and continuity of care should be considered complementary policy objectives rather than inherently competing priorities.

The potential relationship between transaction procedures and product availability is mediated by several operational steps. Documentation requirements, verification of payment purposes, bank processing, and authorization schedules can influence when suppliers receive funds and release shipments. When these steps are predictable, importers can incorporate them into purchasing schedules and inventory planning. Uncertainty may be more disruptive than duration alone, particularly when hospitals maintain limited reserves or products have short shelf lives. Nevertheless, administrative requirements should not automatically be interpreted as the cause of a supply interruption. Manufacturing constraints, transportation delays, procurement decisions, and changes in demand can produce similar downstream effects.

The clinical relevance of foreign-currency procedures is likely to differ across product categories. A delayed shipment of a readily substitutable consumable may be managed through alternative purchasing, whereas interruption of a specialized medicine or a proprietary diagnostic reagent may be harder to accommodate. Patients receiving time-sensitive treatment could be particularly vulnerable when clinical substitution is limited. These pathways are plausible, but they do not establish that any particular transaction requirement causes treatment interruption or adverse outcomes. Such

The American Archives OF MEDICAL SCIENCES EDITOR-IN-CHIEF

© 2026 AAMS Psychiatry & Behavioral Health. All rights reserved.

conclusions would require linked information on financial processing, inventory availability, treatment delivery, and patient outcomes, with adequate adjustment for competing explanations.

Firm-level characteristics may also shape the consequences of compliance. Larger companies may have dedicated regulatory personnel, stronger banking relationships, and sufficient working capital to absorb processing delays. Smaller importers may face proportionally greater administrative costs and less flexibility when exchange rates change between contract agreement and settlement. This asymmetry could influence supplier participation and market concentration, although the direction and magnitude of these effects cannot be assumed. Exporting companies may encounter related issues when receiving or converting foreign-currency earnings, potentially affecting resources available for production or imported inputs. These mechanisms warrant assessment before attributing changes in medical-product prices or competition to currency procedures.

From a policy perspective, the most defensible implication is to improve procedural clarity and predictability while retaining proportionate safeguards. Standardized documentation, transparent processing expectations, and consistent communication between banks, regulators, and trading companies could reduce avoidable uncertainty. For medically essential products, coordinated escalation arrangements may help resolve urgent payment problems without creating blanket exemptions from financial controls. Any expedited pathway should use explicit eligibility criteria, maintain an audit trail, and be evaluated for unintended preferential treatment. Digital submission systems may also be useful, but their benefits depend on interoperability, accessibility, and whether they simplify rather than duplicate existing administrative steps.

Several limitations constrain interpretation. Without a clearly specified national legal framework, conclusions cannot be extended to particular authorization requirements, settlement restrictions, or banking practices. Likewise, the absence of linked patient-level outcomes limits inference about clinical harm. Company-reported difficulties, if used to assess procedural burden, may be influenced by recall, commercial incentives, or selective participation. Measures of processing time may also obscure whether delays arose within companies, banks, regulators, or overseas counterparties. Exchange-rate volatility and broader economic conditions are important potential confounders because they can simultaneously alter transaction behavior, purchasing costs, and product availability. These issues favor cautious, context-dependent interpretation rather than broad causal claims.

Future research should combine transaction timestamps with procurement records, stock availability, and clinically meaningful service indicators. Comparisons across product categories and company sizes could identify where procedural uncertainty has the greatest operational relevance. Evaluations of regulatory changes would be strengthened by appropriate comparison groups and assessment of concurrent policy or market shifts. Overall, foreign-currency transaction procedures merit attention within medical supply-chain research because they may influence the conditions under which essential products are purchased and delivered. The appropriate response is not to presume that fewer controls necessarily improve health outcomes, but to determine which procedural features support lawful trade while minimizing preventable disruption to care. This approach would permit evidence-based refinement of financial oversight without overstating its independent contribution to shortages, costs, or patient harm.

OF MEDICAL SCIENCES

© 2026 AAMS Psychiatry & Behavioral Health. All rights reserved.



Figure 1. Conceptual medical illustration linking delayed import settlement to reduced hospital pharmacy inventory and potential treatment interruption.

5. Conclusion

This study highlights the potential relevance of foreign currency transaction procedures to the continuity of international trade in medicines, medical devices, and other essential healthcare supplies. In the national context examined, companies engaged in export and import operations must follow prescribed procedures when conducting transactions involving foreign currency. These requirements should therefore be considered within assessments of healthcare supply chain resilience, alongside procurement practices, supplier capacity, and transportation constraints.

The implications for health services require cautious interpretation. Administrative complexity, documentation requirements, and the timing of payment authorization may influence procurement schedules, particularly for organizations dependent on imported products. However, procedural requirements alone cannot be assumed to cause shortages, higher treatment costs, or adverse patient outcomes. Such relationships would require direct evaluation using transaction records, inventory data, and appropriately measured clinical or service delivery outcomes.

A balanced policy approach should preserve financial oversight while supporting predictable and transparent processing of legitimate healthcare-related transactions. Clear guidance, coordinated communication between financial institutions and importers, and proportionate administrative requirements may help reduce avoidable uncertainty. Any proposed changes should be assessed for both operational benefits and unintended consequences, including weakened accountability or unequal access among suppliers.

Future research should examine whether transaction processing times are associated with procurement delays and interruptions in essential care, accounting for exchange rate volatility and other supply chain determinants. Overall, foreign currency compliance represents a potentially important operational consideration for healthcare trade, but its independent contribution to health system performance remains to be established.

© 2026 AAMS Psychiatry & Behavioral Health. All rights reserved.

AUTHOR INFORMATION

Shamsiyeva Sumbula[1] Musurmonova E'zoza[2]

Samarkand Institute of Economics and Service. Faculty of Accounting and Auditing[1,2].

REFERENCES

1. International Monetary Fund. (2020). Articles of agreement of the International Monetary Fund.
2. International Monetary Fund. (2012). The liberalization and management of capital flows: An institutional view.
3. World Trade Organization. (2023). World trade report 2023: Re-globalization for a secure, inclusive and sustainable future.
4. United Nations Conference on Trade and Development. (2023). Trade and development report 2023: Growth, debt, and climate: Realigning the global financial architecture. United Nations.
5. Organisation for Economic Co-operation and Development. (2018). Pharmaceutical innovation and access to medicines. OECD Publishing.
6. World Health Organization. (2020). WHO guideline on country pharmaceutical pricing policies (2nd ed.).
7. World Health Organization and Health Action International. (2008). Measuring medicine prices, availability, affordability and price components (2nd ed.). World Health Organization.
8. Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., & Laing, R. (2009). Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis. The Lancet, 373(9659), 240–249.
9. Bigdeli, M., Jacobs, B., Tomson, G., Laing, R., Ghaffar, A., Dujardin, B., & Van Damme, W. (2013). Access to medicines from a health system perspective. Health Policy and Planning, 28(7), 692–704.
10. Goldberg, P. K., & Knetter, M. M. (1997). Goods prices and exchange rates: What have we learned? Journal of Economic Literature, 35(3), 1243–1272.
11. Reinhart, C. M., & Rogoff, K. S. (2004). The modern history of exchange rate arrangements: A reinterpretation. The Quarterly Journal of Economics, 119(1), 1–48.
12. Niëns, L. M., Cameron, A., Van de Poel, E., Ewen, M., Brouwer, W. B. F., & Laing, R. (2010). Quantifying the impoverishing effects of purchasing medicines: A cross-country comparison of the affordability of medicines in the developing world. PLOS Medicine, 7(8), Article e1000333.
13. Bate, R., Jin, G. Z., & Mathur, A. (2011). Does price reveal poor-quality drugs? Evidence from 17 countries. Journal of Health Economics, 30(6), 1150–1163.
14. World Health Organization. (2017). A study on the public health and socioeconomic impact of substandard and falsified medical products.

© 2026 AAMS Psychiatry & Behavioral Health. All rights reserved.

Indexed & Abstracted In

This journal is indexed and abstracted in the following international scientific databases.

Google Scholar

ISSN

ORCID

CiteFactor

ResearchBib

DOI

Zenodo

Crossref

Grammarly



Article Verification

Scan the QR code to verify the authenticity of this article

DOI: 10.4103/aams.0498806

Google Scholar full text: https://www.aams-journal.us/scholar/e7733c26-2acb-4cf7-9be2-a5a14e646226.html

© 2026 AAMS Psychiatry & Behavioral Health. All rights reserved.